Therapy Detail
Contact
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | JNJ-95566692 + Loncastuximab tesirine-lpyl |
| Synonyms | |
| Therapy Description | |
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| JNJ-95566692 | JNJ95566692|JNJ 95566692 | CD20 Antibody 29 CD3 Antibody 128 | Limited information is currently available on JNJ-95566692, a putative trispecific antibody targeting CD79b, MS4A1 (CD20), and CD3 (Feb 2026). | |
| Loncastuximab tesirine-lpyl | Zynlonta | ADCT-402 | CD19 Antibody 24 | Zynlonta (loncastuximab tesirine-lpyl) is a human anti-CD19 antibody in conjugation with a pyrrolobenzodiazepine (PBD) dimer toxin, which may specifically target CD19-positive tumor cells (Blood 2017 130(Suppl 1):187, PMID: 32012214). Zynlonta (loncastuximab tesirine-lpyl) is FDA approved for use in patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy (FDA.gov). |
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT07308132 | Phase I | Cyclophosphamide + Doxorubicin + JNJ-95566692 + Polatuzumab vedotin-piiq + Prednisone + Rituximab Cyclophosphamide + Doxorubicin + JNJ-87801493 + JNJ-95566692 + Prednisone + Vincristine Sulfate Cyclophosphamide + Doxorubicin + JNJ-95566692 + Prednisone + Rituximab + Vincristine Sulfate JNJ-87801493 + JNJ-95566692 + Lenalidomide JNJ-95566692 + Lenalidomide Gemcitabine + JNJ-87801493 + JNJ-95566692 + Oxaliplatin + Rituximab Gemcitabine + JNJ-95566692 + Oxaliplatin + Rituximab JNJ-87801493 + JNJ-95566692 + Loncastuximab tesirine-lpyl JNJ-95566692 + Loncastuximab tesirine-lpyl JNJ-87801493 JNJ-87801493 + JNJ-95566692 JNJ-95566692 Cyclophosphamide + Doxorubicin + JNJ-87801493 + JNJ-95566692 + Polatuzumab vedotin-piiq + Prednisone + Rituximab | A Study of JNJ-95566692 in Participants With Non-Hodgkin Lymphoid Malignancies | Recruiting | TUR | FRA | ESP | BEL | AUS | 0 |
CKB BOOST